ZA200300063B - Inhibitors of copper-containing amine oxidases. - Google Patents
Inhibitors of copper-containing amine oxidases. Download PDFInfo
- Publication number
- ZA200300063B ZA200300063B ZA200300063A ZA200300063A ZA200300063B ZA 200300063 B ZA200300063 B ZA 200300063B ZA 200300063 A ZA200300063 A ZA 200300063A ZA 200300063 A ZA200300063 A ZA 200300063A ZA 200300063 B ZA200300063 B ZA 200300063B
- Authority
- ZA
- South Africa
- Prior art keywords
- disease
- optionally substituted
- condition
- inflammatory disease
- group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 12
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 title description 9
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 title description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- -1 hydrazino compound Chemical class 0.000 claims description 18
- 208000027866 inflammatory disease Diseases 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 10
- 230000004075 alteration Effects 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 8
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 8
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 230000003915 cell function Effects 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Chemical group 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 claims description 3
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 125000003435 aroyl group Chemical group 0.000 claims description 3
- 150000001805 chlorine compounds Chemical group 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 201000005518 mononeuropathy Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 206010035114 pityriasis rosea Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 4
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 206010065673 Nephritic syndrome Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N alpha-methylbenzylalcohol Natural products CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 28
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 26
- 230000000694 effects Effects 0.000 description 14
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 239000000758 substrate Substances 0.000 description 8
- 102000010909 Monoamine Oxidase Human genes 0.000 description 7
- 108010062431 Monoamine oxidase Proteins 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000004968 inflammatory condition Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- BCDGQXUMWHRQCB-UHFFFAOYSA-N aminoacetone Chemical compound CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000056133 human AOC3 Human genes 0.000 description 1
- 102000052278 human ESAM Human genes 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21634100P | 2000-07-05 | 2000-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300063B true ZA200300063B (en) | 2003-07-22 |
Family
ID=22806663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300063A ZA200300063B (en) | 2000-07-05 | 2003-01-03 | Inhibitors of copper-containing amine oxidases. |
| ZA200300064A ZA200300064B (en) | 2000-07-05 | 2003-01-03 | Inhibitors of copper-containing amine oxidases. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300064A ZA200300064B (en) | 2000-07-05 | 2003-01-03 | Inhibitors of copper-containing amine oxidases. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6624202B2 (enExample) |
| EP (2) | EP1301495A2 (enExample) |
| JP (2) | JP2004502682A (enExample) |
| CN (2) | CN1450997A (enExample) |
| AU (3) | AU2001282163B2 (enExample) |
| CA (2) | CA2414799A1 (enExample) |
| HU (2) | HUP0301625A3 (enExample) |
| IL (2) | IL153767A0 (enExample) |
| NO (2) | NO20026283L (enExample) |
| NZ (2) | NZ523464A (enExample) |
| PL (2) | PL360353A1 (enExample) |
| RU (2) | RU2003103291A (enExample) |
| WO (2) | WO2002002541A2 (enExample) |
| ZA (2) | ZA200300063B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1450997A (zh) | 2000-07-05 | 2003-10-22 | 拜奥泰治疗公司 | 含铜的胺氧化酶的抑制剂 |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| TWI336696B (en) | 2003-01-27 | 2011-02-01 | Astellas Pharma Inc | Thiazole derivatives |
| KR20120045062A (ko) * | 2003-03-31 | 2012-05-08 | 가부시키가이샤 아루떼꾸 우에노 | 혈관 과투과 질환의 치료방법 |
| US7499847B2 (en) | 2003-05-26 | 2009-03-03 | Biotie Therapies Corporation | Crystalline VAP-1 and uses thereof |
| FI20031927A0 (fi) * | 2003-12-31 | 2003-12-31 | Faron Pharmaceuticals Oy | Terapeuttisesti vaikuttavia aineita ja niiden käyttö |
| US8119651B2 (en) | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
| FI20040136A0 (fi) * | 2004-01-30 | 2004-01-30 | Faron Pharmaceuticals Oy | Erityisesti diabeetikoille soveltuvia koostumuksia |
| CA2549029A1 (en) * | 2004-01-30 | 2005-08-11 | Faron Pharmaceuticals Oy | Compositions for treatment or prevention of metabolic syndrome |
| FI20040270A0 (fi) * | 2004-02-20 | 2004-02-20 | Biotie Therapies Oyj | Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset |
| DE602005013793D1 (de) * | 2004-07-27 | 2009-05-20 | Astellas Pharma Inc | Thiazolderivate mit vap-1-hemmender wirkung |
| EP1791835A2 (en) * | 2004-09-09 | 2007-06-06 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| JP4140630B2 (ja) * | 2005-11-10 | 2008-08-27 | Ｔｄｋ株式会社 | 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法 |
| US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
| US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
| US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
| FI20061156A0 (fi) | 2006-12-27 | 2006-12-27 | Elina Kivi | Uusia peptidejä |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| US8426587B2 (en) * | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
| TWI437986B (zh) | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途 |
| TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| EP2357252A4 (en) | 2008-09-03 | 2012-05-16 | Univ Barcelona Autonoma | METHOD AND COMPOSITIONS FOR TREATING AND DIAGNOSIS OF A HEMORRHAGIC CONVERSION |
| RU2400233C1 (ru) | 2009-07-07 | 2010-09-27 | Общество с ограниченной ответственностью "Вирфарм" | Способ лечения заболеваний печени различного генеза |
| UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| EP2479165B1 (en) | 2009-09-16 | 2017-10-25 | Astellas Pharma Inc. | Glycine compound |
| RU2010145439A (ru) | 2010-11-08 | 2012-05-20 | Виктор Вениаминович Тец (RU) | Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| KR101879011B1 (ko) * | 2011-03-15 | 2018-07-16 | 아스테라스 세이야쿠 가부시키가이샤 | 구아니딘 화합물 |
| CA2915163A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| HUE042625T2 (hu) | 2014-04-15 | 2019-07-29 | Pecsi Tudomanyegyetem | Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| RU2595868C1 (ru) | 2015-03-27 | 2016-08-27 | Виктор Вениаминович Тец | Лекарственное средство с гепатопротекторной активностью |
| JP2018076236A (ja) | 2015-06-05 | 2018-05-17 | 株式会社アールテック・ウエノ | がんを処置するための医薬組成物 |
| US20180360808A1 (en) | 2015-12-07 | 2018-12-20 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
| CN109810041B (zh) * | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3377345A (en) * | 1966-09-23 | 1968-04-09 | Dow Chemical Co | Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof |
| US3486916A (en) | 1966-12-22 | 1969-12-30 | William A Cordon | Cement mixes and the production of articles therefrom |
| SE320311B (enExample) | 1968-07-15 | 1970-02-02 | Mo Och Domsjoe Ab | |
| WO1993023023A1 (en) * | 1992-05-15 | 1993-11-25 | University Of Saskatchewan | Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis |
| US5413634A (en) | 1993-08-06 | 1995-05-09 | Arco Chemical Technology, L.P. | Cement composition |
| CA2117585C (en) | 1993-09-14 | 2001-06-05 | Edward T. Shawl | Cement composition |
| WO1996006058A1 (en) | 1994-08-25 | 1996-02-29 | W.R. Grace & Co.-Conn. | Shrinkage reduction cement composition |
| US5618344A (en) | 1995-03-06 | 1997-04-08 | W. R. Grace & Co.-Conn. | Cement composition |
| US5556460A (en) | 1995-09-18 | 1996-09-17 | W.R. Grace & Co.-Conn. | Drying shrinkage cement admixture |
| US5603760A (en) | 1995-09-18 | 1997-02-18 | W. R. Grace & Co.-Conn. | Cement admixture capable of inhibiting drying shrinkage and method of using same |
| CN1450997A (zh) | 2000-07-05 | 2003-10-22 | 拜奥泰治疗公司 | 含铜的胺氧化酶的抑制剂 |
-
2001
- 2001-07-04 CN CN01815101A patent/CN1450997A/zh active Pending
- 2001-07-04 CN CN01815102A patent/CN1450998A/zh active Pending
- 2001-07-04 CA CA002414799A patent/CA2414799A1/en not_active Abandoned
- 2001-07-04 HU HU0301625A patent/HUP0301625A3/hu unknown
- 2001-07-04 CA CA002414807A patent/CA2414807A1/en not_active Abandoned
- 2001-07-04 WO PCT/FI2001/000637 patent/WO2002002541A2/en not_active Ceased
- 2001-07-04 AU AU2001282163A patent/AU2001282163B2/en not_active Ceased
- 2001-07-04 JP JP2002507795A patent/JP2004502682A/ja not_active Withdrawn
- 2001-07-04 AU AU2001282162A patent/AU2001282162A1/en not_active Abandoned
- 2001-07-04 AU AU8216301A patent/AU8216301A/xx active Pending
- 2001-07-04 RU RU2003103291/04A patent/RU2003103291A/ru not_active Application Discontinuation
- 2001-07-04 HU HU0301336A patent/HUP0301336A3/hu unknown
- 2001-07-04 IL IL15376701A patent/IL153767A0/xx unknown
- 2001-07-04 NZ NZ523464A patent/NZ523464A/en unknown
- 2001-07-04 IL IL15376601A patent/IL153766A0/xx unknown
- 2001-07-04 JP JP2002506712A patent/JP2004501962A/ja not_active Withdrawn
- 2001-07-04 PL PL36035301A patent/PL360353A1/xx not_active Application Discontinuation
- 2001-07-04 EP EP01960763A patent/EP1301495A2/en not_active Withdrawn
- 2001-07-04 RU RU2003103286/15A patent/RU2003103286A/ru not_active Application Discontinuation
- 2001-07-04 PL PL36037401A patent/PL360374A1/xx not_active Application Discontinuation
- 2001-07-04 NZ NZ523463A patent/NZ523463A/en unknown
- 2001-07-04 WO PCT/FI2001/000638 patent/WO2002002090A2/en not_active Ceased
- 2001-07-04 EP EP01960764A patent/EP1313718A2/en not_active Withdrawn
- 2001-07-05 US US09/898,003 patent/US6624202B2/en not_active Expired - Fee Related
-
2002
- 2002-12-30 NO NO20026283A patent/NO20026283L/no not_active Application Discontinuation
- 2002-12-30 NO NO20026282A patent/NO20026282L/no not_active Application Discontinuation
-
2003
- 2003-01-03 ZA ZA200300063A patent/ZA200300063B/en unknown
- 2003-01-03 ZA ZA200300064A patent/ZA200300064B/en unknown
- 2003-07-21 US US10/622,581 patent/US20040106654A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200300064B (en) | Inhibitors of copper-containing amine oxidases. | |
| EP1414426B1 (en) | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | |
| AU2021382158C1 (en) | Mdma prodrugs to assist psychotherapy | |
| AU2001282163A1 (en) | Inhibitors of copper-containing amine oxidases | |
| US20230233688A1 (en) | Mdma prodrugs to assist psychotherapy | |
| Yeon et al. | Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson’s disease therapy | |
| Cotzias et al. | Monoamine oxidase and cerebral uptake of dopaminergic drugs | |
| EP2098236A1 (en) | Cytostatic compositions | |
| EP1708711B1 (en) | Compositions useful especially for treatment or prevention of metabolic syndrome | |
| US20070093433A1 (en) | Aminoglycoside antibiotics for use as vap-1/ssao inhibitors | |
| CA2084641A1 (fr) | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants | |
| MXPA06000077A (es) | Composiciones que contienen un inhibidor selectivo de la recaptacion de serotonina y un antagonista del receptor 5-ht2a. | |
| WO2005080319A1 (en) | Hydrazino alcohol derivatives useful as inhibitors of copper-containing amine oxidases | |
| US20260091012A1 (en) | Methods Of Treating Meduloblastoma With Thyroid Hormone | |
| WO2025217043A1 (en) | Targeting tet2 enzyme for treating hemoglobinopathies | |
| Zhang et al. | Effects of 1, 1‐dimethylguanidine administration on blood pressure, heart rate and renal sympathetic nerve activity in normotensive and spontaneously hypertensive rats | |
| AU2002354626A1 (en) | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | |
| WO2004056351A1 (ja) | Ｐｋａ活性調節剤 |